• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » VA hospital launches study of CHF Solutions Aquadex FlexFlow device

VA hospital launches study of CHF Solutions Aquadex FlexFlow device

October 11, 2019 By Sean Whooley

CHF Solutions (NSDQ:CHFS) said yesterday that a U.S. Veterans Administration hospital in Florida received approval to begin an outpatient study using its Aquadex FlexFlow system for fluid overload in patients with heart failure.

The study, approved by Tampa’s James Haley Veterans’ Hospital & Clinics institutional review board, will be the first of its kind to run exclusively through the VA.

In July 2018, the department awarded a blanket purchase agreement worth up to $6.5 million for CHF Solutions to supply the Aquadex FlexFlow system for a period of up to five years.

Eden Prairie, Minn.-based CHF Solutions’ Aquadex FlexFlow is an ultrafiltration system designed to remove excess fluid in patients suffering from fluid overload. The platform is indicated for temporary (up to eight hours) and extended (more than eight hours in a hospital setting) ultrafiltration of patients with fluid overload who have failed diuretic therapy.

In March, CHF Solutions touted data from a study that indicated that while the costs of ultrafiltration therapy were higher, fluid removal with ultrafiltration resulted in reduced hospital readmissions and cost savings of approximately $3,975, or 15%, when compared to diuretic therapy. The company acquired the Aquadex device in 2016 for $5 million from Baxter (NYSE:BAX).

CHF Solutions said it submitted an application to the FDA requesting 510(k) clearance for the system to include pediatric patients weighing 44.1 lbs (20 kg) or more.

“We are grateful to be working with JAHVH to initiate a study of the benefits of aquapheresis to manage fluid overload in our nations’ veterans suffering from heart failure,” chairman & CEO John Erb said in prepared remarks.  “Currently, heart failure patients suffering from fluid overload are re-admitted into the hospital, placing a heavy economic burden to the healthcare system.  We look forward to collaborating with the Veterans Administration to offer this treatment in their facilities for heart patients in the out-patient setting and demonstrating the potential savings to the Veterans Health Administration.”

“We are excited about providing great care to our Veterans suffering from fluid overload with the use of ultrafiltration therapy in an outpatient setting,” added JAHVH advanced heart failure program director Ramona Gelzer Bell. “We believe that in addition to improving quality of life, we are reducing the cost of treating patients suffering from fluid overload.  The scientific literature is filled with evidence of the clinical and economic benefits offered by ultrafiltration.”

Shares of CHFS were down -1.4% at $1.44 per share in mid-afternoon trading today.

Filed Under: Cardiovascular, Clinical Trials Tagged With: CHF Solutions Inc., U.S. Veterans Affairs Dept. (VA)

More recent news

  • FDA grants expanded clearance for Levita Magnetics surgical robot
  • FDA adds Gradient denervation tech to advisory program
  • Former Intuitive sales leader joins surgical robot maker Virtual Incision as CEO
  • Smith+Nephew to open first orthopedic ambulatory surgery center in the UK
  • Medtronic partners with IRCAD on Hugo, Affera surgical training

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy